VitaSpring Biomedical: Zero Revenue, High Hopes in Stem Cell R&D

TL;DR

**VitaSpring is a pre-revenue, high-risk biotech bet on unproven stem cell tech, requiring significant capital to even begin commercialization.**

AI Summary

VITASPRING BIOMEDICAL CO. LTD., a development-stage biomedical company, reported no revenue for the fiscal years ended January 31, 2023, and January 31, 2022, as it remains in the research and development phase. The company incurred no R&D expenses during these periods but plans to explore and implement R&D programs once sufficient funding is available. Key business changes include a change of ownership and management effective January 21, 2020, and a corporate name change to VitaSpring Biomedical Co. Ltd. on April 21, 2020. The company focuses on developing cell-based medical technologies, specifically X.msc mesenchymal stem cells and exosome-based materials, derived from ethically obtained non-embryonic human placental tissue. Risks include dependence on third-party research and manufacturing, the ability to raise additional capital, and intense competition in the biomedical and nutraceutical industries. The strategic outlook involves establishing a U.S. FDA-regulated stem cell bank and progressing X.msc-based projects to limited hospital implementation within approximately five years, aiming for commercialization in regenerative medicine, preventive health, beauty, and anti-aging.

Why It Matters

VitaSpring Biomedical's 10-K reveals a development-stage company with no current revenue, relying entirely on future funding and regulatory approvals for its X.msc and exosome technologies. For investors, this signifies extreme speculative risk, as the company is years away from commercialization and faces significant competition from established biotechnology firms. Employees and potential partners must weigh the long-term vision against the immediate lack of operational income and the need for substantial capital. The broader market will watch if VitaSpring can translate its proprietary know-how in cell culture and exosome concentration into viable products, potentially impacting the competitive landscape of regenerative medicine and anti-aging, particularly with its focus on ethical sourcing and strategic relationships in Asia.

Risk Assessment

Risk Level: high — The company explicitly states it 'did not conduct any research and development ("R&D") activities or incur R&D expenses during the fiscal years ended January 31, 2023 and 2022' and currently generates 'only limited revenue,' indicating a complete lack of operational progress and financial self-sufficiency. Furthermore, it has 'no issued patents, registered trademarks, or other registered intellectual property rights' as of the filing date, leaving its core 'proprietary technical know-how' vulnerable.

Analyst Insight

Investors should approach VITASPRING BIOMEDICAL CO. LTD. with extreme caution, recognizing it as a highly speculative, pre-revenue venture. Monitor closely for significant capital raises and concrete R&D milestones, as the company's future hinges entirely on securing funding and advancing its X.msc and exosome technologies through rigorous scientific testing and regulatory approvals.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $0 — Revenue (for fiscal years ended January 31, 2023 and 2022, indicating pre-commercial stage)
• $0 — R&D Expenses (for fiscal years ended January 31, 2023 and 2022, highlighting lack of current research activity)
• 207,030,030 — Shares Outstanding (as of November 26, 2025)
• $14.93 — Bid Price (for common stock on July 31, 2023, indicating illiquidity)
• 5 years — Anticipated Timeline (for X.msc-based projects to reach limited hospital implementation)
• 20 generations — MSC Sub-cultures (proprietary process allows for efficient and stable culture)
• 1,000 times higher — Exosome Concentration (per milliliter compared with conventional MSCs)
• $25 billion — Regenerative Medicine Market Size (exceeded in 2024, indicating significant industry growth)

Key Players & Entities

• VITASPRING BIOMEDICAL CO. LTD. (company) — registrant
• Nevada (regulator) — state of incorporation
• U.S. Food and Drug Administration (regulator) — regulatory approval body
• FINRA (regulator) — Financial Industry Regulatory Authority
• Taiwan National Innovation Awards (award) — received by research and development team
• Ministry of Science and Technology (Taiwan) (regulator) — sponsor of regenerative medicine initiatives
• X.msc (company) — proprietary mesenchymal stem cell
• X.exosome (company) — critical component in skincare and regenerative formulations

FAQ

Risk Factors

• Dependence on Additional Capital [high — financial]: The company is in a development stage and has reported no revenue. Its ability to fund operations, including planned research and development programs, is critically dependent on its ability to raise additional capital. Failure to secure sufficient funding could halt or significantly delay its progress.
• Third-Party Dependence [medium — operational]: VitaSpring relies on third-party research, manufacturing, and supply partners. Any disruptions or failures in these relationships could impede the development, production, and commercialization of its X.msc and exosome-based products.
• Intense Competition [medium — market]: The biomedical and nutraceutical industries are highly competitive. VitaSpring faces competition from established companies and emerging players, which could impact its ability to gain market share and achieve commercial success.
• Regulatory Approvals and Compliance [high — regulatory]: The company's success hinges on obtaining necessary regulatory approvals, such as from the U.S. FDA, for its stem cell bank and therapies. Compliance costs and potential changes in applicable laws pose significant risks.
• Key Personnel and Talent Acquisition [medium — operational]: The company's progress is vulnerable to the loss of key personnel or its inability to attract qualified employees and consultants. Specialized expertise is crucial for research, development, and manufacturing in the biomedical field.

Industry Context

VitaSpring operates in the rapidly growing regenerative medicine and nutraceutical sectors. The regenerative medicine market exceeded $25 billion in 2024, driven by advancements in cell-based therapies. The company's focus on stem cells and exosomes positions it within a highly innovative but competitive landscape, facing both established pharmaceutical companies and emerging biotech firms.

Regulatory Implications

The company's development of cell-based medical technologies, particularly stem cells, subjects it to stringent U.S. FDA regulations. Establishing a U.S. FDA-regulated stem cell bank and progressing X.msc-based projects requires significant investment in compliance and adherence to Good Tissue Practice (GTP) standards. Failure to navigate these regulatory hurdles could prevent commercialization.

What Investors Should Do

1. Monitor funding rounds closely.
2. Evaluate progress on R&D milestones.
3. Assess competitive landscape and differentiation.
4. Track regulatory developments.

Key Dates

• 2016-09-06: Company incorporated in Nevada — Establishes the legal foundation of the company.
• 2020-01-21: Change of ownership and management — Marked a new strategic direction and leadership for the company.
• 2020-04-21: Corporate name change to VitaSpring Biomedical Co. Ltd. — Reflects the company's focus on biomedical endeavors and its new identity.
• 2020-03-30: Filed Certificate of Amendment for name change — Formal step initiating the corporate name change process.
• 2023-01-31: Fiscal year end — Reporting period for the financial statements and operational review.

Glossary

X.msc

A proprietary mesenchymal stem cell technology developed by VitaSpring. (It is a core component of the company's product development strategy for regenerative medicine.)

Exosome

Small vesicles released from cells that carry biomolecules and play a role in cell-to-cell communication. (VitaSpring is developing exosome-based materials, noting a significantly higher concentration in their proprietary MSCs.)

Mesenchymal Stem Cells (MSC)

Adult stem cells that can differentiate into various cell types and are used in regenerative medicine. (VitaSpring focuses on allogeneic MSC processing derived from placental tissue for therapeutic applications.)

Good Tissue Practice (GTP)

A set of regulations and guidelines for the collection, processing, storage, and distribution of human cells and tissues. (VitaSpring aims to establish research and cell production centers meeting these standards, crucial for regulatory compliance and product quality.)

Allogeneic

Derived from a different individual of the same species. (VitaSpring's MSCs are allogeneic, meaning they can be used in a broader patient population without requiring a perfect genetic match.)

Year-Over-Year Comparison

As VitaSpring is a development-stage company with no revenue in the fiscal years ended January 31, 2023, and January 31, 2022, direct year-over-year financial comparisons are not applicable. The company reported $0 in revenue and $0 in R&D expenses for both periods, indicating a consistent pre-commercialization status. Key developments since the prior filing period likely revolve around strategic planning, management changes, and the continued focus on developing proprietary technologies like X.msc and exosome-based materials, rather than changes in financial performance.

Key Financial Figures

• $14.93 b — econd fiscal quarter. On July 31, 2023, $14.93 bid price was reported for our common sto
• $25 billion — e industry reports, the market exceeded $25 billion in 2024 and is projected to continue ex

Filing Documents

• vsbc_10k.htm (10-K) — 832KB
• vsbc_ex311.htm (EX-31.1) — 10KB
• vsbc_ex312.htm (EX-31.2) — 10KB
• vsbc_ex321.htm (EX-32.1) — 4KB
• vsbc_ex322.htm (EX-32.2) — 4KB
• vsbc_10kimg4.jpg (GRAPHIC) — 2KB
• vsbc_10kimg6.jpg (GRAPHIC) — 9KB
• vsbc_10kimg5.jpg (GRAPHIC) — 3KB
• vsbc_10kimg3.jpg (GRAPHIC) — 3KB
• vsbc_10kimg1.jpg (GRAPHIC) — 15KB
• 0001640334-25-002237.txt ( ) — 3876KB
• vbsc-20230131.xsd (EX-101.SCH) — 37KB
• vbsc-20230131_lab.xml (EX-101.LAB) — 221KB
• vbsc-20230131_cal.xml (EX-101.CAL) — 40KB
• vbsc-20230131_pre.xml (EX-101.PRE) — 175KB
• vbsc-20230131_def.xml (EX-101.DEF) — 59KB
• vsbc_10k_htm.xml (XML) — 505KB

BUSINESS

BUSINESS 4 ITEM 1A

RISK FACTORS

RISK FACTORS 10 ITEM 1B UNRESOLVED STAFF COMMENTS 10 ITEM 1C CYBERSECURITY 10 ITEM 2

PROPERTIES

PROPERTIES 10 ITEM 3

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS 11 ITEM 4 MINE SAFETY DISCLOSURES 11 PART II ITEM 5 MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES 12 ITEM 6 RESERVED 13 ITEM 7

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 13 ITEM 7A

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 17 ITEM 8

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 18 ITEM 9 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 19 ITEM 9A

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 19 ITEM 9B OTHER INFORMATION 19 ITEM 9C DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 19 PART III ITEM 10 DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT 20 ITEM 11

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 22 ITEM 12

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 23 ITEM 13 CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE 24 ITEM 14 PRINCIPAL ACCOUNTANT FEES AND SERVICES 24 PART IV ITEM 15 EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 26 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K for the fiscal year ended January 31, 2023 (this "Report") is being filed after its original due date. We are working to regain full compliance with our periodic reporting obligations under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Except as otherwise indicated, all information contained in this Report is presented as of January 31, 2023. This Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Exchange Act. These statements relate to our expectations, beliefs, plans, objectives, intentions, and assumptions regarding future events or performance and are not statements of historical fact. Words such as "may," "will," "could," "should," "expect," "believe," "estimate," "anticipate," "intend," "plan," "continue," "potential," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions, and are subject to known and unknown risks, uncertainties, and factors that could cause actual results to differ materially from those expressed or implied. Important factors that could cause such differences include, but are not limited to: our ability to develop, commercialize, and market our functional-medicine and nutraceutical formulations; our dependence on third-party research, manufacturing, and sup

Business

Item 1. Business. Overview VitaSpring Biomedical Co. Ltd. ("VitaSpring," the "Company," "we," "us," or "our"), formerly known as Shemn Corp., was incorporated in the State of Nevada on September 6, 2016. We are a development-stage biomedical company engaged in the research, development, and commercialization of products that promote wellness and a healthy lifestyle. The Company began operations in 2019 and underwent a change of ownership effective January 21, 2020, resulting in a new management team and strategic direction. In connection with this ownership change, we filed a Certificate of Amendment to our Articles of Incorporation to change our corporate name to VitaSpring Biomedical Co. Ltd., which became effective on April 21, 2020, following clearance by the Financial Industry Regulatory Authority ("FINRA"). Our fiscal year end is January 31. We aim to advance the field of cellular and regenerative medicine through investment in research and development of stem cell–based applications and related biomedical innovations. Our strategic objectives include establishing advanced medical research and cell production centers meeting Good Tissue Practice ("GTP") standards and developing high-quality stem cell preparations for use in regenerative therapies and potential future drug development. In furtherance of these objectives, we collaborate with affiliated entities and research partners to support the mass production and commercialization of X.msc-related medical projects, including investigational new drugs and clinical trials involving X.exosome, a critical component in skincare and regenerative formulations. Management anticipates that X.msc-based projects will progress to limited hospital implementation within approximately five years, as part of our broader plan to integrate laboratory innovation into clinical application. Recent Developments On March 30, 2020, we filed a Certificate of Amendment to our Articles of Incorporation with the Nevada Secreta

View Full Filing

View this 10-K filing on SEC EDGAR